ªÑªF·|­«ÂI
·|­û:fun 10138468 µoªí®É¶¡:2014/6/30 ¤U¤È 10:40:45
ªÑªF·|­«ÂI1.Anti-Cemx ¦~©³°e¥óFDA,¥Ó½Ð¶i¤JIND(·sÃÄÁ{§É¸ÕÅç¡^¡C2.Anti-Cemx °ê»Ú±ÂÅvª÷¦p´CÅé©Ò¨¥¤W¬Ý5»õ¬ü¤¸¤w¤W¡C3.»PGSKñ«O±K¨ó©w,¤´¦b¶i¦æ¤¤¡C4.Xoliar³J¥Õ½è¬Û¦üÃÄ»P¤j³°±á¬P¶°¹Î¹w­p¦~©³Äâ¤â¤j¤¤µØ±ÂÅv¬u²±,°ª¼h¹ï©ó¤½¥q·sÃÄ«H¤ßº¡º¡³á¡I

¬u²±¦~³ø´¦ÅS,2012¦~¥þ²y«e10¤jÃÄ«~,²Ä¤@¦WGSK,¨ä®ð³ÝÃĦ~¾P°âÃB¬°89»õ¬ü¤¸¡C²Ä¤G¦W¬°Abbot,¨äÃþ­··ÃÃö¸`ª¢ÃĦ~¾P°âÃB¬°85»õ¬ü¤¸,³o¨â¶µÃĬҬ°¬u²±¥D¤O²£«~,¥]¬AAnti-Cemx, Xolair, Anti-IL6. ©Ò¥H¤@°_´Á«Ý¦~©³¨Î­µ¡C

·|­û:¥~¦æ¤H10135615µoªí®É¶¡:2017/8/10 ¤U¤È 01:30:13²Ä618½g¦^À³
¤µ¤Ñ¤£¥Î«ü±æ¤U¥b½L©Ô©ï¤F¡Aªi¬q¤j­P¤wOVER
·|­û:¥~¦æ¤H10135615µoªí®É¶¡:2017/8/9 ¤W¤È 09:33:40²Ä617½g¦^À³
8/3¯dªø¤U¼v½u¡Aµu½u¥i¯à´Nout¡F¦p¯¸Ã­26¤¸¥H¤W¡A«hµL®ø®§´N¬O¦n®ø®§¡A´Á«Ý¡I
·|­û:¥~¦æ¤H10135615µoªí®É¶¡:2017/8/4 ¤W¤È 10:28:05²Ä616½g¦^À³
µU¤l¬°¤F¤@®Ú­»¿¼¦Ñ¬O³Q­A¡A¦ý¨Ì½u«¬¬Ý¦n¹³¤S¯d¦³¥ñµ§¡I¡H
·|­û:¥²³Ó10142431µoªí®É¶¡:2017/8/2 ¤U¤È 01:59:29²Ä615½g¦^À³
¦U¦ì¦³¨S¦³µo²{

´CÅé©ñ§Q¦h

¤½¥q­«°T¼á²M

¤j·§´N¬O°ªÂI¤F

·|­û:fun10138468µoªí®É¶¡:2017/7/30 ¤U¤È 10:09:40²Ä614½g¦^À³
¥Í§ÞªÑ³o´X¦~¾ú¸g¸Ñª¼­·­·«B«B¡AµÛ¹ê¥t¤H¤£±Ë»P¼««ã¡C¥»¬O¬ü¨Æ¤@¼Î¡A§Y³yºÖ¤HÃþ¤S¯à¶}³Ð¥xÆW·s²£·~¡C¦ý´CÅéªñ¨Ó¶Ý¦å¦ü¥¼¼f¥ý§P¡AÅý¬ãµo¤H­û»X¨ü·¥¤j¦¾°d»P°d½|¡A¨­·Pµh±¤¡C§Æ±æ´CÅé¤H­û¦b³ø¾É¥ô¦ó¨Æ¥ó®É¡A¥ý§@¨¬¥\½Ò¡A¤~¯à¤½¥¿«ÈÆ[¥­¿Å³ø¾ÉOBI822Á{§É¤G/¤T´Á¹êÅçµ²ªG©Ò¥Nªí·N§t¡C

¯E¹©µoªí©óASCO½×¤åAbstractŪ«á¤ß±o:

a titer ≥ 1:160 &nonresponders:

PFS: HR, 0.52 [95% CI, 0.37-0.71] P< .0001

OS : HR, 0.52 [95% CI, 0.29-0.92] P = .025

Æ[¹îP value< 0.0001 Extremely significant ¡C

Globo H¬°¥Ø«e°ß£¸¥uªí²{¦bcancer cell ¤£ªí²{¦b¥¿±`²Ó­M¤W¡A¦]¦¹¤£¹³Herceptin·|¤Ö³¡¤À¶Ë®`¨ì¥¿±`²Ó­M¡A³Ì¥i¶Q¬OGlobo H vaccine¥i¦P®ÉªvÀø©Ò¦³ER(+),PR(+),HER2,Triple(-)¡C¥Ø«e°ê»Ú¤jÃļtµL¤H¯à¤Î¡C¯f¤H¤£»Ý¹³PD-L1»Ý¨Æ¥ý¿z¿ï¡A¦¹¬Ì­]§ÜÅé¥i¿ëÃÑglobe H,¤Îstem cell ¤Wssea 3 and ssea 4¡A³o¤TºØÁÞ¤À¤lGH series§Ü­ì¦bÀù²Ó­M¡BÀù·F²Ó­M¤W¤À¥¬±µªñ100%¡A©Ò¥H±q¹êÅçµ²ªG±oª¾¡A¥u­n²£¥Í¦³®Ä§ÜÅétiter ≥ 1:160 ¡A§Y¦³·¥ÅãµÛ©ÊÀøªk¡C

¥Í§ÞªÑ§Y±N§_·¥®õ¨Ó¡A³ß¨ÆÁ{ªù¡C¬u²±ªñ´Á¦¨¥æ¶q«ùÄò©ñ¤j¡A¦b¦b»¡©ú¦³¨Æµo¥Í¡C¬u²±©Î³\¤]±N³¶«Ì¤¤¿ïÀò±o°ê»Ú¤jÃļt«C·ý¡A±ÂÅv¦¨¥\¡C«¥­Ì«ø¥Ø¥H«Ý¡C

udn.com/news/story/7254/2612564

·|­û:¾ÖÅ@ªÌ10140685µoªí®É¶¡:2017/7/27 ¤U¤È 01:40:45²Ä613½g¦^À³
¤@ªi¨ì³»¨«¶Õ

µ´¤j¦h¼ÆÀ³¸Ó³£¿ù¹L¤F

¦pªG¥¼¨Ó¦³¥D¤É¬qªº¸Ü

§Æ±æ¤j®a³£¯à¦³¾÷·|°Ñ»P

·|­û:¥~¦æ¤H10135615µoªí®É¶¡:2017/7/27 ¤U¤È 12:50:33²Ä612½g¦^À³
³QÀ~¨ì¤F¡I¶]¤@¤Uµu½uµL¥i«p«D¡F¦ý¬Ý¤£¥X¤j¤H¦³¯h¾ÎºA¡H
·|­û:¾ÖÅ@ªÌ10140685µoªí®É¶¡:2017/7/26 ¤U¤È 12:29:56²Ä611½g¦^À³
º¦¨ì¤j®a³£¶Ì²´¤F

¤£ª¾¹Dµo¥Í¬Æ»ò¤j®a³£¤£ª¾¹Dªº¨Æ¤F

¤S©Î³\¤°»ò¨Æ³£¨S¦³

¥u¬O³æ¯Â¥D¤Oª£§@¬°¤F¦Û¤v¸Ñ®M¦Ó¤w

·|­û:ROGER588910144700µoªí®É¶¡:2017/7/26 ¤W¤È 09:14:19²Ä610½g¦^À³
©Ç©Ç!¦³¤HÂP¨ì¬Æ»ò®ø®§¥i§_³zÅS¤@¤U???

·|­û:¤p¶Â½Þ10140151µoªí®É¶¡:2017/7/24 ¤U¤È 03:47:12²Ä609½g¦^À³
¥H«e³o´X¤Ñ³oºØ¶q¡A¤µ¤Ñ¬u²±¦Ü¤Ö50¤¸¤F¡A¦ý¦]¬°¨ó©M¤jªÑªFÀò§Q¤Fµ²¡]¥xÆW²{¦b¤jªÑªF¯àÁȨì¿ú¡AÀ³¸Ó´N¥u¦³¨ó©M§a¡A¨ä¥L¤£¬O¤W¤£¤F¿³Âd¡A´N¬O³QÂê¡A¯u¬O°ª©Û°Ú¡ã¡^¡A¤£ª¾¹D¥L¤â¤WÁÙ¦³¦h¤Ö¡H­Y·íªì¬O3ªÑ´«1ªÑ¬Æ¦Ü2ªÑ´«1ªÑ¡A¦Ü¤Ö½æ¶q¨S¨º»ò¤j°Ú¡C

µ²ªG³y¦¨¤µ¤Ñ­ì©l¬u²±ªÑªF¨ü·l¡A¤Wº¦ÁÙ³Q©ì²Ö¡ã

­ì©l¬u²±¤pªÑªFªºÅv¯q¦ó¦b°Ú¡ã

·|­û:¤p¶Â½Þ10140151µoªí®É¶¡:2017/7/21 ¤U¤È 05:50:16²Ä608½g¦^À³
§Úªº·N«ä¨Ã«D»¡¨ó¦X·sÃĨS¦³»ù­È¡A¦Ó¬O®Ú¾Ú¤W¦¸ªºªk»¡·|¡A¥¼¨Ó¤T¦~®Ú¥»¨S¦³ÃD§÷¥i¥Hª£§@¡A¦b¥xÆW¡A¥D¤O¥u°µ¦³ÃD§÷ªºªF¦è¡A¤£¬O¦³»ù­Èªº¡C

­Y¬Ý»ù­È¡A¥H«eªº¬u²±¡A¤]À³¸Ó­n¦³3¦ì¼ÆªºªÑ»ù¡A¬°¦ó¤@ª½¶^¨ì2¢æ¡H´N¬O¦]¬°ÃD§÷¥¼¨ì¡A¥D¤O¤£«æµÛ¶i³õ¡CªO¤WªºªB¤Í¡AÀ³¸Ó¤]µ¥¤F¨â¤T¦~¡A¤µ¦~¤]³\´N§Öµ¥¨ì±ÂÅv¡A²{¦b­IµÛ¨ó©M¡A¨ì®É¯uªº±ÂÅv¡AªÑ»ù­¸±o°_¨Ó¶Ü¡H

²{¦bÁÙ¤£ª¾¹D³o¥D¤Oªº¤ßºA¬O¦p¦ó¡H¬O¤£¬O¤]¬O¬Ý·Ç±ÂÅv®É¶¡®t¤£¦h¡A¶}©l¶i³õ½ä¤@§â¡A¦ý±ÂÅv­Y¬OÁÙ¬O»»»»µL´Á¡A¥D¤O¤@°h³õ¡AÁÙ¬O·|¶^¦^°_º¦ÂI.......

·|­û:ROGER588910144700µoªí®É¶¡:2017/7/21 ¤U¤È 05:29:17²Ä607½g¦^À³
¤@®a¤½¥qÁÙ¨S¦³·sÃĤW¥«¹s¦¬¤J³º­È102»õ¬ü¤¸,Àù¯g·F²Ó­M¹Ú¦³¦h¤j!

2016.4¤ëAbbVie¯{¤U¹dÃB¤Ñ»ù102»õ¬ü¤¸¦¬ÁÊStemcentrx¤½¥q©ãª`Àù¯g·F²Ó­M

Stemcentrx¤½¥q¦³¤­Ïú试验©Ê·s药¡A¨ä¤¤¤TÏú¤w¦b¦­´Á临§É试验¤¤¨ú±o¤F¥i³ßªº结ªG¡A¥t两Ïú¤]¥¿处¤_I´Á»PII´Á临§É试验阶¬q.

·|­û:¤p¶Â½Þ10140151µoªí®É¶¡:2017/7/21 ¤U¤È 01:57:11²Ä606½g¦^À³
§Ú­Ó¤H§PÂ_¬OÀ³¸Ó¨S¦³¯S§O®ø®§¡A·|º¦ªº²z¥Ñ¡A³æ¯Â¬O¦³¥D¤O¶i¨Ó¡A¥Ø«e¬Ý°_¨Ó¬u²±¥u¬O¨ä¤¤¤@¤ä¡A¦Ó¥L­Ì¬Dªº¼Ðªº¡A³£¬O·¥¦³¼ç¤O¡A¦ýªÑ»ù³QÄY­«§C¦ô¡A¤µ¤ÑªÑ»ù¤@¤f®ð©Ô¨ì40-50¤]¨SÔ£¦n·N¥~¡A¦]¬°³o¤]ÁÙ¨S¨ì¦X²zªÑ»ù¡C

­Y¸s¯qª÷¹©¨º¦ì¤j¤á°±¤î½æ¡AÀ³¸Ó·|©Ô§ó§Ö¡A³o°}¤l¥L¨C¤Ñ½æ50±i¡A¬Q¤Ñ¶X¶Õ½æ186¡A¨S·N¥~¡A¤µ¤ÑÀ³¸Ó·|½æ300±i¥H¤W§a¡C

¦]¬°®õºÖ³Ìªñªº·s»D¡AÅý§Ú·Q¨ì¬°¦ó¨ó©M·sÃĤ£¦Û¤v¤W¿³Âd¡A¦Ó¬O¸ò¬u²±¦X¨Ö¡Aµª®×À³¸Ó´N¬O³o­Ó

¡yÃÒ¥æ©Ò26¤é³q¹L®õºÖ-KY¤W¥«¥Ó½Ð®×¡A¨ä¤¤²Ä¤T¶µ¡A­n¨D¤½¥q¤§¸³¨Æ¡B«ùªÑ¶W¹L¤wµo¦æªÑ¥÷Á`ÃB¦Ê¤À¤§5¤§ªÑªF¡BÁ`¸g²z¤Î¬ãµo¥DºÞ¡A©Ó¿Õ¨ä¨Ì¥»¤½¥q¡u¦³»ùÃÒ¨é¤W¥«¼f¬d·Ç«h¡v²Ä28±ø¤§9²Ä2¶µ³W©w´£¥æ¶°¤¤«OºÞ¤§ªÑ²¼¡AÀ³¦Û¤W¥«¶R½æ¶}©l¤é°_©¡º¡1¦~«á¡A¥B¸Ó¤½¥q¤½§i¥Ó³ø¤§°]°È³ø§iµ|«e·l¯q¬°¥¿¼Æ¡A©l±o»â¦^2¤À¤§1¡A«S±o»â¦^¶°¤¤«OºÞªÑ²¼¶}©l¤é°_©¡º¡1¦~«á©l±o¥þ¼Æ»â¦^¡C¡z

¦pªG·Q­n¿³Âd¡A¨S°ÝÃD¡A°ÝÃD¬O¤£¯à½æªÑ²¼¡A¹ï¬Y¨Ç¤jªÑªF¦Ó¨¥¡A¿³Âd´N¨S·N¸q¤F¡A¦Ó¨ó©M­nµ¥¨ì¯àÀò§Q¡A¨S3-5¦~¬O¤£¥i¯àªº¨Æ¡A¥Î¨Öªº°¨¤W´N¥i¥H½æ¡C

¦Ñ¹ê»¡¡A¦X¨Ö§Ú¬O¨S·N¨£¡A¦ý¥Î³o»ù®æ¨Ö¡A®Ú¥»¬OÄ묹¬u²±¤pªÑªFªºÅv¯q

·|­û:ROGER588910144700µoªí®É¶¡:2017/7/21 ¤U¤È 12:39:10²Ä605½g¦^À³
¦³¿c¨ì¤°®ø®§­n¤£¤À¨É¤@¤U?
·|­û:¥~¦æ¤H10135615µoªí®É¶¡:2017/7/21 ¤W¤È 09:27:49²Ä604½g¦^À³
¤j¤H¤S¨Ó®ø»º¤F¡I
·|­û:¤p¨Æ10135609µoªí®É¶¡:2017/7/20 ¤U¤È 12:37:18²Ä603½g¦^À³

¨ØªA

·|­û:§Ú¨Ó¤F10141579µoªí®É¶¡:2017/7/20 ¤W¤È 08:14:55²Ä602½g¦^À³
¥_·¥20~40

¦]µØ18~26

§C»ù¥ÍÂåªÑ·|ÃþªÑ½ü°Ê¶Ü¡H

¥H¤W½Ð¤Å°Ñ¦Ò

·|­û:§Ú¨Ó¤F10141579µoªí®É¶¡:2017/7/19 ¤W¤È 10:50:46²Ä601½g¦^À³
³o¨â¤Ñ¦³§C±µ¶R½L⋯
·|­û:ROGER588910144700µoªí®É¶¡:2017/7/15 ¤W¤È 08:26:17²Ä600½g¦^À³
©³¤UCSCS´£¥X½èºÃªºÃIJz¾÷¨î:...¦ýlong-liveªº¼ß²Ó­MFB825¸òQuilizumab±þ¤£±¼¡A³o¨Ç¥i¯àÁÙ¬O·|«ùÄò²£¥Í·|»{¹L±Ó­ìªºIgE¡A¦Ó¥BÁÙ¦³±qIgG memory BÅܦ¨IgE memory Bªº¸ô®|¡A©Ò¥HIgE¦³¤U­°¦ý¯gª¬¨S¦³§ïµ½¡C

¨º»ò¬u²±»P²Ä3²Õ¤H°¨ÁÙ¦P¨B¶}µo§ÜC£`mX¬Ì­]»Panti-EMPD¬Ì­]?

:¥»¤½¥q«Ø¥ß¤§§ÜC£`mXªvÀø¹L±Ó©Ê¯e¯f·sÃħ޳N¥­¥x¡A°£¶i¦æAnti-C£`mX ³æ

®è§ÜÅéFB825¶}µo¥~¡A¦P¨B¶}µo§ÜC£`mX¬Ì­]¡A¥»¦¸³q¹L¬ü°ê±M§Q¦WºÙ¬°¡uC£`mX

peptides for inducing immune responses to human mIgE on B lymphocytes¡v¡A

±M§QÃҮѦr¸¹8,974,794¡C

³o¤@½g2016.7¤ë²Ä4²Õ¹Î¶¤ªF¨Ê²z¬ìµoªí¦bNature Immunology:

Autonomous membrane IgE signaling prevents IgE-memory formationµy¨£ºÝ­Ù.

....Our findings reveal an autonomous mIgE signaling mechanism that normally prevents IgE+ Bmem and LLPC formation

http://www.nature.com/ni/journal/v17/n9/full/ni.3508.html

·|­û:ROGER588910144700µoªí®É¶¡:2017/7/10 ¤W¤È 11:45:01²Ä599½g¦^À³
¤d½u¸U½u¤£¦p³o¤@±ø½u!

ñ´»CDA¦³¨S¦³Ã¹¤ó»P¿ÕµØ???

§äµo¨¥¤H¥H³Ì¦­Ã±¸pªºG®a....ÂPÂP¬Ý!

Xolair¥Ñù¤óRoche(¬ü°ê¥«³õ...)©M¿ÕµØNovartis(¼Ú¬w¥«³õ)Áp¦X¾P°â.

ªñ¦~xolair±M§Q³°Äò¨ì´Á,ù¤ó©M¿ÕµØ­n·Q¤è³]ªk¾d©T®ð³ÝëC³Â¯l¥«³õ,¦]¦¹QuilizumabÁ{§É®É·í¥H®ð³ÝëC³Â¯l¬°Àu¥ý.

­Y2®a³£¦³Ã±CDA,¨º»ò²Õ¦XÀøªkFB825+ xolair´N¬O¤@¿ï¶µ,°£¤FÀ±¸Éxolair¦]Ige¤ô¥­»PÅé­«ªº­­¨î±ø¥ó¦ÓµLªk¬I¥´ªº±wªÌ.

¤]¯à¹ïXolair¥Íª«¬Û¦üÃħΦ¨«Ì»Ù.

·|­û:¾ÖÅ@ªÌ10140685µoªí®É¶¡:2017/7/10 ¤W¤È 08:59:45²Ä598½g¦^À³
¨S¿ù,Á{§É¥¼¤½¥¬«e,½Ö³£»¡¤£·Ç

©êºp,¤Ö¥´¤@¦r¤F

·|­û:¾ÖÅ@ªÌ10140685µoªí®É¶¡:2017/7/10 ¤W¤È 08:54:20²Ä597½g¦^À³
¨S¿ù,Á{§É¥¼¤½¥¬«e,½Ö³£»¡·Ç

¬O§_³]©wªº°Ñ¼Æ,±ø¥ó·|¼vÅTµ²ªG?

´N¦³½ÐC¸òR¤j¸ò¤j®a¸ÑªR¸ÑªR

¦]¤W¦¸¤½¥q¦³´£¨ì,ù¤ó³]©wªº¤£¬O«Ü¦n

·|­û:¥~¦æ¤H10135615µoªí®É¶¡:2017/7/9 ¤U¤È 08:59:55²Ä596½g¦^À³
¬JµM³£¤w¸g³Q®M¤F¡A·Q¶}¤@ÂI§_«hÅåÀ~°h³õ¤£´NÁ«¤j¤F¡C

¥Í§Þ§Ú¬Oªù¥~º~¡A¦ý´¶Ã¹¤j²³¦³½Ö¨º»ò¼F®`¥i¥H»¡±o·ÇÁÙ¤£¬O¸ÕµÛ°µ¨«µÛÁ@¡A§ó¦óªp§Ú­ÌÁÙ¦³¤¤¬ã°|¡B¥x¤j¡B¡Bµ¥±M·~»â°ì¹Ù¦ñ¥B¦³¶°¹Î§ë«H©Mª¾¦W¤j©@¬Û¦ñÀH¡C

·|­û:ROGER588910144700µoªí®É¶¡:2017/7/7 ¤U¤È 11:46:06²Ä595½g¦^À³
¨ó©Mªº¸~½F·F²Ó­M°ö¾i·f°t¬u²±ªº¥þ¤H§ÜÅé®w¥­¥x¿z¿ï¥X§ÜÅé­Ô¿ïÃĪ«

³o¤G®a¤£¨ã¦³¤¬¸É©Ê?

¦b¦P¤@®a¤½¥qªº­û¤u·|·d¬£¨t°«ª§,¦óªp¬O¤£¦P®a­û¤u?

·|­û:ROGER588910144700µoªí®É¶¡:2017/7/7 ¤U¤È 11:40:27²Ä594½g¦^À³
¯u¦³³o»òÁV¿|!

·R´þÀù¯g¯à¦³²Õ¦XÀøªk,¦Û¨­§K¬Ì¯e¯f´N¦æ¤£³q?

Ige¤ô¥­¶W¹L­­¨î¤£¯à¬I¥´?

¤½¥qºô­¶©ú¸üFB825©MXolair(©ÎFB317)¦X¥Î¡Aµo´§¬Û­¼¥\®Ä¡A¨Ã´î§CXolairªº¥Î¶q¡A¤Î­°§C¹L±Ó±wªÌ»PÂåÀø¨t²Îªº¸gÀÙ­t¾á

6/30°ê®õªk»¡·|²³ø¤¤­««×¹L±Ó©Ê®ð³Ý¤´¦CªvÀø¾AÀ³¯g,¦bP2aµ²ªG¥X¨Ó©ÎFB317®³¨ìÃÄÃÒÀ³¸Ó´N·|Á{§É²Õ¦XÀøªk?

Anti-M1¡¦ / Anti-C£`mX/ anti-EMPD ¦U¦ÛºÙ¸¹.

2017¦~²Ä3²Õ¤Hªº³ø§i:

¡K. Based on our in vitro findings, we propose that Ce3 targeting could be combined with EMPD targeting to further exploit possible additive effects similar to what was observed with our in vitro combinations ( Fig. 2C). Our observation might spur future clinical modalities, including established anti-IgE therapies. As an example, the obvious group of allergic asthma patients that are currently not eligible to Omalizumab therapy due to excessive IgE levels and/or body weight ( Cohen et al., 2014 ; Liour et al., 2016) might benefit from such combined anti-IgE therapies involving soluble IgE targeting and human EMPD IgE targeting

http://www.sciencedirect.com/science/article/pii/S0022175917300650

·|­û:cscs10144679µoªí®É¶¡:2017/7/7 ¤U¤È 09:49:31²Ä593½g¦^À³
¹ï©ó¦¹¦X¨Ö®×¥uı±o¬O¾Þ§@¡A¦P¶°¹Îªº¤½¥q¦³»Ý­n¦X¨Ö?

¤j·§¬O¨ó©M¿³Âd«ÜÃø¡A¨Ö¦¨¬u²±ªÑ²¼´N¯à½æ¤F¡A

¤S¦h¤@°ïªÑ²¼¯à½æ¿ú¤F

·|­û:¥~¦æ¤H10135615µoªí®É¶¡:2017/7/7 ¤U¤È 09:37:10²Ä592½g¦^À³
ªÑÅv¶W¹L¤@¥bªº¥x¤j¡B¤¤¬ã°|¤Î½²¦ÑÁó¤S¦p¦ó·|¦P·N¦¹¤@¦X¨Ö®×
·|­û:¥²³Ó10142431µoªí®É¶¡:2017/7/7 ¤U¤È 09:31:49²Ä591½g¦^À³
·PÁÂcscs¤jªá®É¶¡¤Q¤À¸ÔºÉ¦a¸Ñ»¡¡A¯Â¬ì¾Ç²z©ÊÀËÅç

ÃĪ«§@¥Î¾÷¨î¡A¤W¤FÄ_¶Qªº¤@½Ò¡A´CÅé¤@¸ô³ø³ß¤£³ø

¼~¡AªÑ»ù¤Ï¬M¤@®a¤½¥qªº»ù­È¡A¦A¶Ìªº¤H¤]µoı¤£¹ï

¤F¡C

·|­û:¾ÖÅ@ªÌ10140685µoªí®É¶¡:2017/7/7 ¤U¤È 09:23:29²Ä590½g¦^À³
¥i¯à¤½¥q¤]·NÃѨì¤F

©Ò¥HÂX¤j¾AÀ³¯g,¥Ó½Ð©t¨àÃÄ

¬°FB825¥t´M¥X¸ô

·|­û:¥~¦æ¤H10135615µoªí®É¶¡:2017/7/7 ¤U¤È 08:56:52²Ä589½g¦^À³
¦p¦¹¤£´N³´¤JªdÕ襤¡A¦ý¤G¦~«eÂà¨ü4¸U¦h±iªº©@¤£¤]¬O«ÜÁV¿|¶Ü¡H

·|­û:cscs10144679µoªí®É¶¡:2017/7/7 ¤U¤È 05:51:53²Ä588½g¦^À³
Roger¶Kªº¤å³¹·Q»¡Åý§A¸ÑÄÀµ¹¤j®a¬Ý¡A§Ú´N¤£¥Î¥´¤@°ï¦r¤F¡A

´N¬ì¾Ç¤W¨Ó±´°Q¡A§Ú¬O½Ö¨Ã¤£¼vÅT§ÜÅ骺§@¥Î¾÷¨î¡C

¤Þ­zAnti-IgEÃĪ«ªvÀø¡uºC©ÊëC³Â¯l¡vªº¾÷¨î±´°Q¸Ìªº¤º®e¡A

°ò¥»¤W¡A¤j³¡¥÷ªº¹L±Ó²{¶H¡A³£¨Ó¦Û¤HÅ餺ªº§K¬Ì²Ó­MIgE¤À¤l¡C¦b¸û­ì©lªºÀô¹Ò¸Ì¡A¦]¬°¦³³\¦hªº±H¥ÍÂε¥·P¬Vª«¡AIgE¤§©Ò¥H

¦s¦bªº¥D­n§@¥Î¡A´N¦b©ó¥D§ð³o¨Ç¯f­ìÅé¡C·í·P¬Vµo¥Í®É¡AIgE·|¶}©l¤j¶qªº¥X°Ê¡A¶e¨ì³o¨Ç¥~«Iª«¡A¨Ã¥B©M¥Ö½§¼h¤ºªº¡u¥¨¤j

²Ó­M¡v(mast cells)¤Wªº¨üÅéµ²¦X¡C

¥¨¤j²Ó­M¬O¤HÅé²£¥Íµoª¢¤ÏÀ³ªº¥D­n¨¤¦â¡A¦h¦s¦b©ó¥Ö½§¼h¡A·íIgE©Ô¨ì¥~¨Ó·P¬Vª«ªº§Ü­ì(antigen)¸g¥Ñ©M¥¨¤j²Ó­Mªº¨üÅé

(receptor)¡AºÙ¤§ Fc£`RI¡A²£¥Í±µÄ²«á¡A¥¨¤j²Ó­M´N¶}©l¬¡¤Æ¡A¦b§Ü­ì¥æ¤e³s±µ«á(Crosslink)¡A¥¨¤j²Ó­M¶}©l¬¡¤Æ¡A²£¥Í¦UºØ

Äè¼Äª«½è¡A¥]¬A²Õ´Ói¡B¨x¯Àµ¥¡A·í¥¨¤j²Ó­M±N³o¨Çª«½èÄÀ©ñ¥X¨Ó®É¡A¤]´N¬O¬°¤°»ò§Ú­Ì¨­Å馳µoª¢²{¶Hªº­ì¦]¡C¦¹¥~¡A¶ÝÆP©Ê

²Ó­M¡A¬O©M¥¨¤j²Ó­M©Ê½è¬Û¦üªº§@¥Î¡A¤]¦³Fc£`RI¨üÅé¡A¥u¤£¹L¥¦¬O¦b¦å²G¤º¬y°Êªº¡C

¹L±Ó²{¶H¥ÑIgE©Ò³y¦¨¡A´î¤ÖÅ餺IgEªº¶q´N¯à¦³®Ä´î½w¯gª¬¡Aomalizumab¯à³o»ò¦³®Ä´N¬O¥¦¯à¨³³tªº¤¤©M¦å²G¸ÌªºIgE¡A

Åý³o¨ÇIgE¤£·|¦A¸ò¨üÅéµ²¦X¡A¤£·|¦A«ùÄòªº²£¥Í¹L±Ó¤ÏÀ³¡C

¤¤©M¤§«áÅ餺ÁÙ¬O·|Ä~Äò¥Í¦¨IgE¡A©Ò¥H­n2~4¶gÄ~Äòª`®g¡A¤~¯à±±¨î¯f±¡¡C

·íÅ餺IgE¤Ó°ª®É¡AomalizumabµLªk§¹¥þ¤¤©M¦å²G¸ÌªºIgE¡A¦]¬°¤~·|³]©w¨Ï¥Î½d³ò30~1300IU/mL¡A

¶W¹L1300IUªº¯f±w¤£·|¨Ï¥Îomalizumab¡A

AD¯f¤HªºIgE¦³¨Ç³£«D±`°ª¡A¬Æ¦Ü¨ì¤W¸U¡A¥Îomalizumab¬°¦ó¦³®Ä?±À´úªº¾÷¨î¥i¯à¬OIgE:omalizumab immune complexes¡A

³o¨ÇIgE-omalizumabµ²¦Xª«¦bÁÙ¦b¥NÁ±¼¤§«e¡A¦bÅ餺¦³¹³¹L±Ó­ì²M°£¾¯ªº¥\¯à¡A

¦]¬°¹L±Ó­ì³QIgEµ²¦X¤F¡A¦ý¤S¤£¯à¸ò¨üÅéµ²¦X¡A©Ò¥H¤£·|¤Þ°_¹L±Ó¤ÏÀ³¡A

·íµM³o¬O±À´úªº¡A«Ý½T»{¡C

FB825¸òQuilizumab³£¬O°w¹ïC£`mX¡A¤]ºÙ§@M1¡¦ªº°Ï°ì¡A³o¬O¦b½¤«¬IgE B²Ó­M¤Wªº¤@­Ó°Ï°ì¡A¦å²G¸Ìªº¤Àªc¥X¨ÓªºIgE´N¨S¦³³o

¤@³¡¤À¡C

oncohemakey.com/biology-of-the-b-lymphocyte/

¬Ý¹Ï8.1

¦¹¬°B²Ó­M¤À¤Æªº¹Lµ{¡AB²Ó­M¦¨¼ô¨ì³Ì«áÅܦ¨¼ß²Ó­M(plasma cell)¡A¼ß²Ó­M¬OÅ餺¥Í¦¨§ÜÅ骺²Ó­M.

¤À¤Æ¨ìmemory Bªº®É­Ô¡A²Ó­Mªí­±ÁÙ¦³½¤«¬ªºIg, ¦pIgA, IgG, IgE,

FB825¸òQuilizumab°w¹ïªº³£¬O±a¦³½¤«¬IgEªºB²Ó­M¡A©Ò¥H±þ±¼±a¦³½¤«¬IgEªºmemory B¤§«á´N¤£·|¥Í¦¨IgE¼ß²Ó­M¡A¶i¦Ó´î¤ÖIgEªº¥Í¦¨¡C

¤@¼Ë¬O´î¤ÖIgE¦ý¾÷¨î¬O¤£¦Pªº¡A¦b¯S©wIgE¿@«×¤Uomalizumab¥i¥H§â­ì¦³ªºIgE³£²M°£±¼¡A¦pªG¬O«D±`°ªIgEªº¡A

¥i¯à¤]¦³immune complexesªºÀ°§U¯à²M°£¹L±Ó­ì¡A¦]¦¹¯gª¬¦³§ïµ½¡C

FB825¸òQuilizumab¯àªý¤î·s¥Í¦¨IgEªº¸ô®|¡A¦ýÅ餺­ì¦³ªºIgE¨Ã¤£·|²M°£¡A

³¡¤À²£¥ÍIgEªº¨Ó·½³Qªý¤î¤F¡A¦ý­ì¦³ªºIgEÁÙ¬O¦³¯à³y¦¨¹L±Ó²{¶Hªº¼Æ¶q¡A

¼ß²Ó­M¦³long-live»Pshort-live 2ºØ¡Aµu©Rªº·íµM¤ñ¸û§Ö¦º±¼¡A«áÄò¤£¼vÅT¡A

¦ýlong-liveªº¼ß²Ó­MFB825¸òQuilizumab±þ¤£±¼¡A³o¨Ç¥i¯àÁÙ¬O·|«ùÄò²£¥Í·|»{¹L±Ó­ìªºIgE¡A

¦Ó¥BÁÙ¦³±qIgG memory BÅܦ¨IgE memory Bªº¸ô®|¡A©Ò¥HIgE¦³¤U­°¦ý¯gª¬¨S¦³§ïµ½¡C

IgE¦³»{¹L±Ó­ì»P¤£»{¹L±Ó­ìªº¡A·|»{¹L±Ó­ìªºIgE¥i¯à¦û¥þÅéIgEªº´X%¦Ó¤w¡A¦ý³o´X%ªºIgE´N¯à³y¦¨¹L±Ó¯e¯f¡C

OmalizumabÁöµM¤]±þ¤£±¼long-live IgE¼ß²Ó­M¡A¦ý¥¦¯à¨³³t¦³®Ä­°§C¦å²G¤¤ªºIgE¡A´N¬O¦³®Ä¡C

FB825®ÄªG¤ñ¸û¦n?¥u¾a¤½¥qªº§ë¼v¤ù¬O¬Ý¤£¥X¯uªºµ²ªG¡ARoche°µ§¹Á{§É³£µopaper¸Ô²Ó»¡©ú¡A

FB825ªºµ²ªG¦b­þ?¦³´X¤ÀÃÒ¾Ú»¡´X¤À¸Ü¡A§Ú¼gªºªF¦è¤£·|Åý§A·Q¶RªÑ²¼¡A¤£·|Åý§A½ß¿ú¡A

§Ú¤]»¡¤F¡A¤G´Áµ²ªG¥X¨Ó¦A»¡¡A¤Ó¦­»¡¦³¦h¦n¦h¦n³£¬OªÅ½Í¡A

²³¦h®ø®§¸ÌÁÙ¬O­n²z©Êªº§PÂ_¤ÀªR¡A¦³¨Ç¤H¨S¦³¬ÛÃö­I´º¡A

µLªk¤ñ¸û¸Ô²Óªº¤F¸ÑÃIJz¾÷¨î¡A¥ú¾a®ø®§­±¨Ó¨M©w¡A¹ê¦b¬O¥Rº¡­·ÀI¡A

ÁöµM»¡°ª­·ÀI°ª³ø¹S¡A¦Û¤v²z¸Ñ§¹¨M©w¦Û¤vªº§ë¸ê¡A¦p¦¹¦Ó¤w¡C

·|­û:ROGER588910144700µoªí®É¶¡:2017/7/7 ¤U¤È 12:38:08²Ä587½g¦^À³
·Q·Q¤]¬O!´Nºâñ´»CDA¦³¥]§tù¤ó,

¥H¦ûÀù¯gÃĪ«¥«³õ³Ì¤jÀYªºÃ¹¤ó,»¡¤£©w¦³¿³½ì¬Û¤¤ªº¬O¬u²±¿W¨B¥þ²y¤§¸~½F·F²Ó­M°ö¾i¡B·sÃÄ¿z¿ï¥­¥x

·|­û:¾ÖÅ@ªÌ10140685µoªí®É¶¡:2017/7/7 ¤U¤È 12:14:09²Ä586½g¦^À³
©Î³\¤j®a·Qªº¥i¯à³£¬Û¦ü.

ù¤ó2´Á°µ§¹¤£°µ¤F

¬O§_·|ª½±µ¨ÓÃöª`®ÄªG¸û¦nªºFB825

·|­û:¥²³Ó10142431µoªí®É¶¡:2017/7/7 ¤W¤È 11:35:47²Ä585½g¦^À³
§O¦h¦¹¤@Á|

¬J¬O«O±K¨óij¦ÛµM¥]§tñ¬ù¹ï¶H

«ç¥i¯à¦^µª§A

·|­û:¾ÖÅ@ªÌ10140685µoªí®É¶¡:2017/7/7 ¤W¤È 11:35:07²Ä584½g¦^À³
ROGER¤j:

¦³Ãø«×°Ú,ªB¤Íªº¦P¾Ç¥h¦~¤U¥b¦~¤wÂ÷¶}¤F¦¹¤½¥q

·|­û:ROGER588910144700µoªí®É¶¡:2017/7/7 ¤W¤È 11:29:57²Ä583½g¦^À³
¾Ö¤j:

³Ò±z¦V¤½¥q±´¸ß©³¤U·s»D¨Æ¥óñ´»CDA¦³¥]§tù¤ó?

¦³«h§ó¥¿­±¼ÖÆ[

2017-01-12 01:10¸gÀÙ¤é³ø

¤p¼¯¥ÍÂå¦~·|¡A¥x¼t¨ü«C·ý¡C¥x¼t°Ñ¥[¼¯®Ú¤j³q°ê»Ú¥ÍÂå¦~·|¡]J.P. Morgan Healthcare Conference¡^¶Ç¨Ó³ß°T¡A¥]¬Aù¤ó¡B¼b¥Í¡B§¨Ó¡B¿ÕµØµ¥°ê»Ú¤@½u¤j¼t¶}¥X±ø¥ó¡A±N§ÞÂà¥x¼t§ÜÅéÃIJ£«~¡A¨ä¤¤¬u²±¡B¦X¤@µ¥¤½¥qªº²£«~§Þ³N¸ß°Ý«×°ª

«á¨Ó¤½¥q¼á²M»¡©ú:¥»¤½¥q¤w»P¦h®aÃļtñ´»CDA¡A¬ÛÃö¨Æ©y§¡¶·¿í¦u«O±K¨óij

·|­û:ROGER588910144700µoªí®É¶¡:2017/7/7 ¤W¤È 10:52:57²Ä582½g¦^À³
XolairÀòFDA®Ö­ãªº2ºØªvÀø¯e¯f:®ð³Ý/ºC©ÊëC³Â¯l

1.Anti-IgEÃĪ«ªvÀø¡uºC©ÊëC³Â¯l¡vªº¾÷¨î±´°Q

Xolair ªº§@¥Î¦b©ó¤¤©M¤HÅ餺ªº§K¬Ì§ÜÅéIgE¡C¾ã­Ó¥Ö½§¾Ç»PÁ{§É§K¬Ì¾Ç¬É¹ïXolair¬°¦ó¯àªvÀøCSU¡uºC©ÊëC³Â¯l¡v·P¨ì¤£¸Ñ¡Chttp://www.genomics.sinica.edu.tw/index.php/tw/news/news-archives/429-anti-ige

2.http://www.e-jmii.com/article/S1684-1182(11)00267-2/pdf

......IgE levels and eosinophil percentages are not good indicators for a prolonged course

of urticaria(ºC©ÊëC³Â¯l). (AD±wªÌ»PIgE levels°ª«×¦³Ãö)

http://www.e-jmii.com/article/S1684-1182(11)00267-2/pdf

·|­û:ROGER588910144700µoªí®É¶¡:2017/7/7 ¤W¤È 10:25:00²Ä581½g¦^À³
Xolair¤W¥«¾P°â§Ö15¦~©|¦³ÃĪ«¾÷¨îIgE:omalizumab immune complexes«Ý½T»{!

FB825»PQuilizumabªºÃĪ«¾÷¨î±z¤w§¹¥þºN²M?

«¥µù¥U½s¸¹¡G10144700,±z¦­«¥´X¸¹.

±zªº¨­¤À¤£¥~3ºØ¥i¯à©Ê:¬u²±Â÷¾­û¤u/¥Ñ·RÂà«ë¦a§ë¸ê¤H/¨ä¥L?

¦pªG¬u²±¦b¦­¨Ç¦~ªº¤¤°ª»ù¦ì,±zªº¨¥½×«¥¯à»{¦P!

¦Ó©Ò¶Kªº¬ã¨s³ø§i¦®¦bªí¹FAD¤¤­««×±wªÌ(extrinsic¥~¦]©Ê)»P°ªIge¤ô¥­¤GªÌ¶¡ªºÃö³s©Ê¤ñQuilizumabÁ{§ÉªºAllergic asthma; Allergic rhinitis; Urticaria¶¡§ó©úÅã!

·|­û:cscs10144679µoªí®É¶¡:2017/7/7 ¤W¤È 09:03:54²Ä580½g¦^À³
R¤j­n¤£­n¸ÑÄÀ¤@¤U2012¨º½gpaper¡A»¡©ú¬°¦ó¶W°ªIgEªºAD¯f¤H¨Ï¥Îomalizumab¡A

§Y«KµLªk§¹¥þ¤¤©MIgE«oÁÙ¬O¦³¯f±w¦³§ïµ½?

OmalizumabªºÃIJz¾÷¨î¸òFB825ªº¤£¦P¦b­þ?

·|­û:¾ÖÅ@ªÌ10140685µoªí®É¶¡:2017/7/6 ¤U¤È 03:40:53²Ä579½g¦^À³
ROGER¤j:

¬Ý±o¥X¨Ó,§A¹ïFB825«Ü¦³«H¤ß

·sÃij̫á¯à¦¨¥\ªº¯uªº¤£¦h

¤]§Æ±æ¤½¥q¤£­nÅý§ë¸ê¤H¥¢±æ

·|­û:ROGER588910144700µoªí®É¶¡:2017/7/6 ¤U¤È 02:27:54²Ä578½g¦^À³
FB825¦bÁ{§ÉP1¥´1°w­°40~50% ;¥xÆWÁ{§ÉP2a¥´3°w!

³Ì«á´£¨Ñ¤G½g³ø§i¼fµøAD±wªÌtotal Ige­°40~50%¯gª¬·|¤£·|§ïµ½?

¥t¥~¥þ²y¿W¨B±M§Q¤§¸~½F·F²Ó­M°ö¾i»P¿z¿ï¥­¥x·|¤£·|¤Þ°_°ê»Ú¤jÃļtª`·N?

1. 2012¦~±i¤l¤å

Among patients with atopic dermatitis, the proportion with IgE above 700 IU/mL is much larger than that for adult allergic asthma: it is common to find atopic dermatitis patients with serum IgE even higher than 10,000 IU/mL.....dermatitis, the IgE levels are too high to be neutralized by affordable doses of omalizumab. (¥xÆW¹L±Ó®ð³Ý±wªÌallergic asthma¥´1°womalizumab¬ùNT$15000)

http://www.sciencedirect.com/science/article/pii/S102781171200095X

2.·Ó¤ù²³æ©öÀ´! 2017 April

¹ÏA /B total Ige±q17,183 IU/mL­°¨ì11,983 IU/mL(¬ù­°30%).

http://www.mdedge.com/cutis/article/136166/atopic-dermatitis/severe-refractory-atopic-dermatitis-elevated-serum-ige

·|­û:¾ÖÅ@ªÌ10140685µoªí®É¶¡:2017/7/6 ¤W¤È 09:03:04²Ä577½g¦^À³
±q2016¦~1¤ë¦Ü¤µ¦@1¦~¥b®É¶¡ùØ

«ù¦³1000±i¥H¤W¤jªÑªF±q¥¼¦³°Ê§@

¤W©P¬ðµM¼W¥[7¦Ê¦h±i

³o.........

·|­û:¾ÖÅ@ªÌ10140685µoªí®É¶¡:2017/7/5 ¤U¤È 08:51:21²Ä576½g¦^À³
2´ÁÁ{§É¦¨±Ñ,±N¨M©w¤@¤Á

·|­û:¾ÖÅ@ªÌ10140685µoªí®É¶¡:2017/7/5 ¤U¤È 07:50:19²Ä575½g¦^À³
cscs¤j:·Pı§A¬O¥Í§Þ°é¤º¤H

¬Ý¨ÓªÑ»ùªu¸ô¯}©³ªº­ì¦]

¬O¦­¦³¤Hª¾¹DFB825¦¨¥\¾÷²v§C

·|­û:¥²³Ó10142431µoªí®É¶¡:2017/7/5 ¤U¤È 06:36:30²Ä574½g¦^À³
¬Ý§¹cscs¤jªº¸ÑÄÀ

¤~ª¾¹D¦Û¤v¤Ó¹à¤F

¬Ý³ø¯Èª±ªÑ²¼

«ç»ò¦ºªº³£¤£ª¾¹D

·|­û:cscs10144679µoªí®É¶¡:2017/7/5 ¤U¤È 05:10:02²Ä573½g¦^À³
MEDI4212µ²¦XIgEªº¿Ë©M¤OÁöµM°ª¡A¦ý¥¦¸ÑÂ÷ªº³t«×¤ñXOLAIRÁÙ§Ö¡A

³y¦¨¦å²G¸ÌIgE¿@«×¦^´_ªº³t«×¤ñXOLAIRÁÙ§Ö¡A¬Û¸û¤§¤U´N¤ñ¤£¹LXOLAIR¡C

UB221»PCD23¤W­±ªºIgE§@¥Î¡A¬O§_¯à§ó¥[´î¤ÖIgEªº¥Í¦¨¡A¯uªº¨S°µÁ{§É¤£ª¾¹D¡A

«ù¥­¬Ý«Ý§a

·|­û:ROGER588910144700µoªí®É¶¡:2017/7/5 ¤U¤È 04:39:49²Ä572½g¦^À³
¹L»P¤£¤Î¡A¬Ò¦³¥¢¤§¡A¨D¤¤±e¡C

UB-221¨ã¦³¤£¦P©óXolair®ªº§@¥Î¾÷¨î¡A°£¤F¥i¥H¤¤©M¤Þµo¹L±Ó¤ÏÀ³ªº¥D­n¤À¤lIgE¡A¤]¥i³z¹L»P(CD23)¨üÅé¤WªºIgEµ²¦X®ÄÀ³

MedImmuneªºmedi4212¤¤©MIge±j©óXOLAIR 10­¿¤S¦p¦ó? SAE¹L¤£¤FÃö´N¬O¥¢±Ñ¦¬³õ,«öC¤jªº±À²z­ì«h UB-221¤]¤£®e¼ÖÆ[???

MEDI4212 potently inhibited responses through Fc£`RI and also prevented the binding of IgE to CD23. When used ex vivo at identical concentration, MEDI4212 depleted free-IgE from human sera to levels ~1 log lower than omalizumab

https://kclpure.kcl.ac.uk/portal/en/publications/a-novel-igeneutralizing-antibody-for-the-treatment-of-severe-uncontrolled-asthma(19cb9e9d-0e97-4b72-bfc7-6fcd88f4f1ef).html

·|­û:cscs10144679µoªí®É¶¡:2017/7/5 ¤U¤È 01:13:13²Ä571½g¦^À³
¨Ó¦^ÂФ@¤UFB825»PUB221¡A

¬u²±±ÂÅvFB825®É¡AUB221ÁÙ¨S°µ¦n¡A

FB825¦³¿W¯S©Ê¡A°£¤FROCHE¨S¦³¨ä¥¦¤H¦³¡A

UB221­±«e¦³XOLAIR³o®y¤j¤sÀY¡A­n¶W¶V¥¦¤£¬O³o»ò®e©ö¡A

¦Ó¥BÁÙ¦³¨ä¥¦Ävª§ªÌ¤]¦b±Æ¶¤¤F¡C

UB221»PXOLAIR³£¬O°w¹ïfree IgE¡A

ÁöµMUB221ÁÙ¦³¤£¦Pªº¯S©Ê¡A¦¹¯S©Ê¦³¥i¯à¥h­°§CIgEªº¥Í¦¨¡A

·íµM³o¥u¬O²z½×¤W¡A¹ê»Ú¤W·|¤£·|¤ñXOLAIR±j¡A³o­Ó¤j·§­n§¹¦¨Á{§É¤~¯à±o¨ìµª®×¤F¡C

Áp¥ÍÃĦ³¿³½ì·íµM´N§ÞÂà¡A¦pªG¨S¤H¦³¿³½ì´N¥u¬O©ñµÛ¡A¤£·|¦Û¤vµo®i¡C

FB825ªº½T¤]¦p¹w´Á¯à±þ±¼½¤«¬IgEªºB²Ó­M¡A¶i¦Ó´î¤Ö²£¥ÍIgE¡A

¦ý¦³¨Ç¬¡«Ü¤[ªºIgE¼ß²Ó­M·|¤@ª½²£¥ÍIgE¡A¦å²G¤¤ªºIgE¤U­°¤FÁÙ¬O¤£ºâ§C¡C

¦bIgE¤£¬O«Ü°ªªº¯f±w¨Ó»¡¡A¨Ï¥ÎXolair¥i¥H°¨¤W­°§C¦å²G¤¤ªºIgE¡A

ÁöµM­n«ùÄò¬I¥´¡A¦]¬°¯à¦³®Äªº²M°£IgE¡A©Ò¥H¯gª¬¯à±o¨ì§ïµ½¡C

FB825­n°w¹ï°ªIgEªº¯f±w¡A°²³]¬O1500IU¥H¤W¡A´î¤Ö50%ÁÙ¬O¦³750IU¡A

Å餺³oºØ¿@«×ªºIgE¥i¯àÁÙ¬OÅý¯gª¬«ùÄò¡A¨Ã¨S¦³§ïµ½¡A

¦óªp¦³¨Ç¯f¤HªºIgE¬O§ó°ªªº¡A³æ¾a³o¼Ë´N­n¦³Àø®Ä¬O¤£¬O¨º»ò®e©ö¡A

¾Ö¤j¡A

respiratory-research.biomedcentral.com/articles/10.1186/s12931-016-0347-2

Quilizumab¦b¤ñ¸ûÄY­«ªº®ð³Ý¤¤¨Ã¨S¦³±o¨ìÀø®Ä¡AFB825¤]¤£·|¥h°µ³o¼Ëªº¹Á¸Õ¡A

©Ò¥H¥u·|¬D¨ä¥¦¾AÀ³¯g¡A©Î¬O­n¥h¥Ó½Ð©t¨àÃÄ¡A¨ä¥¦¾AÀ³¯g¤£¤@©w¦³®Ä¡A©t¨àÃĤ@¦~ªº¥«³õ¨Ã¤£¤j¡A¦Ó¥B°w¹ï°ªIgE¯f±wÁÙ¬O¹J¨ì¦P¼Ëªº°ÝÃD¡C

¥²³Ó¤j¡A

²q´ú¤£¬O½Í±ÂÅv¤~©ì©µÁ{§É®Éµ{¡A¦­ÂI°µ§¹Á{§É¤~¯à¦­ÂI¥X°â¡A

«e´£¬O­n¦³®Ä¡A¬Ý¨ìRocheªºµ²ªGÀ³¸ÓÅý¬u²±¦b¦Ò¼{­n¤£­n°µ¤U¥h¤~ºC¤F¸}¨B¡A

°Ñ¦ÒRocheªºqulizumab¤ñ¸û±µªñFB825ªºÃIJz¾÷¨î¡C

quilizumab¤£Ä~Äò¤F¡AFB825ÀY³£¬~¤F¤]¥u¯àÄ~Äò¤U¥h¡A

¤@¨Ó¬O¨S°µ¨ì³Ì«á·íµM¤£ª¾¹Dµ²ªG·|¦p¦ó¡A¤G¨Ó¬O²{¦b°±¤F´N¬O»{¿é¡A

¤]¨S¦³¸ÜÃD¥iª£¡A©Ò¥H¤G´ÁÁÙ¬O­nÄ~Äò°µ¡C

·|­û:¾ÖÅ@ªÌ10140685µoªí®É¶¡:2017/7/5 ¤U¤È 12:25:41²Ä570½g¦^À³
2´Á¹L¤F¦A¨Ó½Í±ÂÅv,»ù½X¤~·|¤ñ¸û¦n

¤~¤@´Á¹L¤F¤½¥q´N«æµÛ±ÂÅv

®ö¶O§Ö1¦~ªº®É¶¡

·|­û:¥²³Ó10142431µoªí®É¶¡:2017/7/5 ¤W¤È 11:47:53²Ä569½g¦^À³
¾Ö¤j

®ð³Ý¯f¥ÎÃÄÄvª§¤Ó¿E¯P¡A§äÄvª§¸û¤ÖªºÂÅ®üÀ³¸Ó¬O¤½¥qªº

µ¦²¤¡A§Úªº¬ÝªkFB825©Î³\¦³½Í±ÂÅv¦]¦¹©ì©µÁ{§É®Éµ{¡A

¥i¯à¬O³Ì«á¨S½Í¦¨¡A²{¦b¤~¶}©l°µÁ{§É¡A¤£¹LºCÁ`¤ñ¥¢±Ñ

¦n¡C

§Ú­n¦^À³¥»¸ÜÃD
·|­û:
§@ªÌ:
¬ÛÃöªÑ²¼¤½¥q¦WºÙ:¬u²±¥Íª«¬ì§Þ
¤º®e:
½Ð¥ýµn¤J­Y±z©|µL·|­û¨­¤À¡A½Ð¥ý¥Ó½Ð±b¸¹
°Q½×°Ï¬ÛÃö³W©w¡G
1.­Y±b¸¹¶¢¸m¹L¤[¨t²Î·|¦Û°Êµn¥X¡A«ØÄ³¦b¼g¦n¤å³¹¨Ã¥B©|¥¼µo°e¤§«e¥ý¦æ½Æ»s¡A¥H§Kµo°e¥¢±Ñ«á¾É­P¤º¤å®ø¥¢¡I
2.½Ð¤Å°Q½×ªÑ²¼¶R½æ©Î´£¤Î¦¨¥æ»ù¦ìµ¥¨Æ©y¡A¤Z¬O¯d¤U¬ÛÃö¥æ©ö°T®§¡A¥»ºô±N¦Û°Ê§R°£¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
3.ÄY¸T¯d¤UÁpµ¸¤è¦¡¡A½Ñ¦pLINE¡BFB¡BE-mail¡B¹q¸Ü..µ¥¡A©Î¥H¥ô¦ó©ú¥Ü¡B·t¥Üµ¥¤âªk¶i¦æÁpµ¸¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
4.¬°Á×§K®ö¶Oºô¸ô¸ê·½¡A½Ð¤Å±N¬Û¦P¤º®e³sÄòµo¦b¦h­Ó¤£¦P¥DÃD¤º¡A©ÎªÌ³sÄòµo°e¦h­Ó·s¥DÃD¡A­Y¦³¦¹Ãþ¬~ª©¤§¦æ¬°±NµLªkÄ~Äò°Ñ»P°Q½×¡I
5.ÄY¸T·N¹ÏÂǥΥ»ºô¥­¥x¤½µM´²¥¬¤å¦r©ó²³¡A¦Ó«üÂÖ¡B«V°d©Î¶Ç­z¨¬¥H·´·l¥L¤H¦WÅA¤§¨ÆªÌ¡A­Y¦]¦Ó¯A¤Îªk«ß°ÝÃD¡A·§»P¥»¤½¥qµLÃö¡A·q½Ð¿í¦u¡C

·q½Ð´L­«¥»ºô¤§¸gÀç²z©À¨Ã¿í¦uª©³W¡AÁÂÁ¡C

¼s§i¦X§@ ¥¼¤W¥«ÂdªÑ²¼¬d¸ß ¥¼¤W¥«ºô¯¸¾ÉÄý ¥¼¤W¥«ÂdªÑ²¼±MÃD ¿³ÂdªÑ²¼±MÃD ¥¼¤W¥«ªÑ²¼-¶°¹Î¤ÀÃþ ²§·~Âà§ë¸ê¥Í§Þ·~ ¤U³æ±Ð¾Ç
¥¼¤W¥«|¥¼¤W¥«ªÑ²¼|³Ì±M·~ªº  ¥xÆW¥¼¤W¥«ªÑ²¼  °]¸gºô¯¸-Copyright©2022¡£¥²´Iºô¡¤ §K¥I¶OªA°È±M½u:0800-035-178 ªA°È«H½c:postmaster@berich.com.tw
¥»ºô¯¸¬° ¥¼¤W¥«ÂdªÑ²¼¬d¸ß,¥¼¤W¥«ªÑ²¼§Y®É·s»D,¥¼¤W¥«¤½¥q¤½§i,¿³ÂdªÑ²¼¶R½æ,·Ç¤W¥«ªÑ²¼,¤¤ÅҪѬÛÃö¸ê°T¤À¨É¥æ¬yªÀ¸sºô¯¸,¸ê®Æ¶È¨Ñ°Ñ¦Ò,¨Ï¥ÎªÌ½Ð¦Û¦æ·r°u!
¥»ºô¯¸¤£¤¶¤J·|­û¶¡¤§¥¼¤W¥«ªÑ²¼¶R½æ,³æ¯Â´£¨Ñ¥¼¤W¥«ªÑ²¼¦æ±¡,«ùªÑÂàÅý,¥¼¤W¥«ªÑ²¼¹L¤á¿Ô¸ß¶È´£¨Ñ¥¼¤W¥«ªÑ²¼¥æ©ö¥­¥xµ¹·|­û¨Ï¥Î,¨Ì¥»¸ê®Æ¥æ©ö«á¬ÕÁ«¦Û­t!